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A risk model for febrile neutropenia (FN) after conventional cytotoxic chemotherapy, based on early (day 5) lymphopenia and the
dose of chemotherapy, has been described. A risk index based on parameters available at day 1 would be easier in daily practice. The
objectives of this work were (1) to investigate a risk model for FN using only day 1 blood cell count and (2) to compare the day 1 and
day 5 risk models. Three series of patients were used for the delineation and/or validation of these two risk models: (1) the
exhaustive cohort of 950 patients treated in the Department of Medicine of the CLB in 1996 (CLB-1996 series), (2) the Elypse 1
series, a prospective series of 321 patients treated in community hospitals and regional cancer centres, and (3) a previously reported
Elypse 0 series of 329 patients. Day 1 blood cell count was available in all three series, while day 5 blood cell count was available only
in the Elypse 0 and 1 series. In the CLB-1996 series, 92 (9.7%) patients experienced FN; only chemotherapy dose and day 1
lymphopenia p700ml
 1 had an independent prognostic value for FN in multivariate analysis. In patients with both risk factors (‘high-
risk group’), the incidence of FN was 44, 50 and 61% in the CLB-1996. Elypse 1 and 0 series, respectively, indicating that the ‘day 1’
risk model enables one to identify patients at high-risk for FN. Besides, the observed incidence of FN in the high-risk group of the ‘day
5’ model (i.e. patients with day 5 lymphopenia p700ml
 1 and receiving high-risk CT) was 45 and 69% in the Elypse 0 and 1 series,
respectively. In the Elypse 1 and 0 series, 15 and 12% of all patients who experienced FN were in the high-risk group of the ‘day 1’ risk
model as compared to 25 and 62% for the high-risk group of the ‘day 5’ risk model. Both day 1 and day 5 lymphopenia are associated
with an increased risk of FN in patients treated with chemotherapy. The ‘day 1’ model identifies a small population of patients at high
risk for FN, but has a lower sensitivity than the day 5 model.
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Febrile grade four (PMNp500ml
 1) neutropenia (FN) is a frequent
complication of cancer chemotherapy, which causes death in 4–
21% of patients in large studies (The International Antimicrobial
Therapy Group, 1978; Bodey, 1986; Pizzo et al, 1987; Talcott et al,
1992; Klastersky, 1993; Bodey et al, 1996; Segal et al, 2001). The
risk of FN after administration of chemotherapy not only depends
on the type and doses of drugs administered, but also on
individual risk factors for each patient, such as performance
status (PS), coexisting infections or underlying immunosuppres-
sion (Bodey, 1986; Klastersky, 1993; Bodey et al, 1996; Segal et al,
2001). Hence, even after the administration of a dose-intensive
chemotherapy regimen, 30–50% of the patients will not experience
FN, while conversely, FN will occur in 2–15% of the patients who
receive chemotherapy regimens with conventional doses of drugs
(Miser et al, 1987; Tannock et al, 1988; Velasquez et al, 1988;
Coiffier et al, 1989; Elias et al, 1989; Nichols et al, 1991).
The identification of simple and readily available clinical and
biological risk factors for FN after the administration of cytotoxic
chemotherapy is an important goal for the selection of candidate
patients for prophylactic measures to FN, in particular adminis-
tration of granulocyte growth factors (The American Society of
Clinical Oncology, 1994; Blay et al, 1995; Boogaerts et al, 1995;
Bennett et al, 1999). We previously reported that the occurrence of
an early lymphopenia (p700ml
 1) at day 5 following the
administration of chemotherapy was an independent risk factor
for FN along with the type of chemotherapy regimen in four series
of patients treated in comprehensive cancer centres (Blay et al,
1996). In this prognostic model, a high-risk subgroup of patients
with both risk factors (i.e. receiving ‘high-risk’ chemotherapy and
with a day 5 lymphocyte count p700ml
 1) was identified, with an
observed incidence of FN of 69%. This subgroup includes 62% of
patients who experienced FN in this previous study (Blay et al,
1996). This model is currently used as inclusion criteria in a
prospective randomised study comparing the use of G-CSF in
primary or secondary prophylaxis. However, the use of day 5
lymphocyte count for the quantification of the risk of FN was
found to be not optimally practical for outpatient care, since the
patient is identified at high risk after having left the hospital.
Although day 1 lymphocytes count was not significantly correlated
to the risk of FN in the previous study, the observed incidence of
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lFN in this subgroup was 440%, suggesting that it may have been
missed because of a lack of power of the study (Blay et al, 1996).
Supporting this hypothesis, baseline day 1 lymphopenia was found
to be an independent risk factor for other haematological
toxicities, in particular severe anaemia (Ray-Coquard et al,
1999), severe thrombopenia (Blay et al, 1998) and early death
(Ray-Coquard et al, 2001) after cytotoxic chemotherapy.
To address this issue, a risk model for FN based on day 1
lymphocyte count was delineated in a large series of 950 patients
(CLB-1996). The prognostic value of the two risk models for febrile
neutropenia, relying respectively on day 1 and day 5 haematolo-
gical parameters, was then tested and compared in two validation
series.
PATIENTS AND METHODS
Selection criteria for patients
Selection criteria for patients in all series were identical and as
follows: age above 17 years, negative human immunodeficiency
virus (HIV) serology in patients with non Hodgkin’s lymphoma,
and chemotherapy regimens administered sequentially, that is
every 8 or more days. All patients treated with cytotoxic
chemotherapy were included, regardless of the number of previous
courses. Exclusion criteria were: a diagnosis of low-grade
lymphoma or leukaemia because of the possible contamination
of peripheral blood by malignant lymphocytes, administration of
cytokines or granulocyte growth factors during or after che-
motherapy, and high-dose chemotherapy regimen requiring bone
marrow or peripheral-blood stem-cell reinjection. Information
about histology, primary tumour site, chemotherapy regimen,
sex, age, PS, blood cell count on day 1 (d1) just before
the administration of chemotherapy and on day 5, and FN
following the studied chemotherapy course were collected. In the
CLB-1996 series, the history of FN was not available for the
majority of the patients, and therefore not collected. This
information is available for the Elypse 1 series only. Each patient
was analysed for only one course of chemotherapy. No prophy-
lactic antibiotics were used in any series. Patients’ characteristics
are indicated in Tables 1 and 2.
Description of the patients
CLB-1996 series This series is the exhaustive cohort of patients
treated with conventional chemotherapy regimens in the Depart-
ment of Medicine of the Centre Le ´on Be ´rard in 1996 who matched
the selection criteria (Table 1). There were 3223 chemotherapy
courses given to 1116 patients. Patients previously treated outside
the centre were eligible. Patients with a missing blood cell count at
day 1 (n¼65) and receiving G-CSF or GM-CSF (n¼101) after the
course were excluded. Therefore, 950 of the 1116 patients (85%)
were eligible and analysed.
Elypse 1 series The prospective cohort (Elypse 1) is a multicentric
prospective series of 321 patients treated with conventional
chemotherapy in both general community hospital (n¼13) and
regional cancer centres (n¼5): 84 patients (26%) were treated in
cancer centres and 237 (74%) in general community hospitals
(Table 1). Every participating physician had to include all his
consecutive patients during 1 month (chosen by local investigators
for each institution) between November 1995 and September 1996.
Each patient was followed for two consecutive courses of
chemotherapy.
Elypse 0 series This series has already been described in the
initial publication of the day 5 risk model (Blay et al, 1996). It
comprises 329 patients evaluated in the test and validation samples
of the previous publication, that is: (1) a retrospective series of 112
consecutive different patients treated in the Department of
Intensive Chemotherapy of the Centre Le ´on Be ´rard between June
and December 1992; (2) a prospective series of 142 patients treated
in the Centre Leon Be ´rard between April and June 1993; (3) a
prospective series of 36 patients treated with chemotherapy in the
Institut Gustave Roussy between January 1994 and March 1994 and
(4) a series of 39 patients treated with ACVBP within prospective
protocols of the GELA group (Blay et al, 1996).
Chemotherapy regimens Chemotherapy regimens were separated
into two subgroups according to the doses of drugs administered.
The first group, termed ‘high-risk’ regimens, includes highly
cytotoxic regimens with a high expected incidence of neutropenia
and FN as defined in previous works of the Elypse group (Blay et al,
1996, 1998; Ray-Coquard et al, 1999, 2001). High-risk regimens
were defined on the basis of the initial recommendations of the
French Ministry of Health for the use of G-CSF or GM-CSF, which
was restricted to those patients receiving regimens including at
least these doses of chemotherapy (for anthracyclines, alkylating
agents, and VP16). For CDDP and cytosine arabinoside, the
thresholds of doses chosen were those used internally, within the
CLB, to select patients for primary prophylaxis with G-CSF or GM-
CSF. ‘High-risk’ chemotherapy regimens are defined as follows:
these are regimens containing doxorubicin or epirubicin
X90mgm
 2, or cisplatin X100mgm
 2, or ifosfamide X9gm
 2,
or cyclophosphamide X1gm
 2; or etoposide X500mgm
 2,o r
cytarabine X1gm
 2 per course. The other subgroup includes all
other chemotherapy regimens.
Statistical analysis
Risk factors for FN were tested in univariate and multivariate
analysis using the procedures of the SPSS
s 10.0 program (SPSS,
Inc., Chicago, 2000) on the CLB-1996 series of patients, in which
only the haematological parameter measured at day 1 were
available. The correlation between a clinical or a biological
parameter and the incidence of chemotherapy-induced FN was
performed using the w
2 test or the Fisher exact test. Logistic
regression including the studied parameters of the univariate
analysis was performed using the logistic program of SPSS 10.0
s:a
forward regression procedure was used with a P value o0.05 for
entry. Risk factors (e.g. PS41) and the end point (i.e. FN) were
dichotomised. Parameter estimates for independent risk factors
were determined and compared to previous risk model (Blay et al,
1996). This new risk model and the previous risk model (day 5 risk
model) (Blay et al, 1996) were then compared in the Elypse 1 and 0
series. Finally, the sensitivity, specificity, positive predictive value,
and negative predictive value (NPV) of the model were calculated.
The relative risk of the high-risk group is estimated as the positive
predictive value divided by 1-NPV.
RESULTS
Risk model for FN using day 1 blood cell count
The predictive value of day 1 blood cell count for the risk of FN
was investigated in the CLB-1996 series, which includes 950
patients treated in 1996 in the Department of Medicine of the CLB.
A total of 92 (9.7%) experienced an FN. In univariate analysis,
‘high-risk’ chemotherapy, PS41, tumour type, and female sex
were significantly correlated to the risk of FN (Table 1). Among
day 1 haematological parameters, only day 1 lymphocytes
p700ml
 1 were found marginally (P¼0.052) correlated to the
risk of FN in the CLB-1996 series (Table 2). Comorbidity, age,
tumour stage, day 1 haemoglobin, platelet, and neutrophil count
did not correlate to the risk of FN in the CLB-1996 series (Tables 1
and 2). In the multivariate analysis, day 1 lymphocyte count and
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l‘high-risk’ chemotherapy were identified as the only two
independent risk factors for FN in this series (Table 3). This
enables one to delineate a risk model for FN in which day-1
lymphopenia o700ml
 1 is used instead of day-5 lymphopenia
used in the previous model (Blay et al, 1996) (Table 3). In this
variant ‘day 1’ model, the observed incidence of FN in patients
with 0, 1, and 2 of these two risk factors was found to be 8, 13, and
44%, respectively, in the CLB-1996 series (Table 4). The relative
risk of FN in the high-risk group is 4.75 compared to the
intermediate plus low-risk groups.
Prognostic factors for FN in the Elypse 1 and 0 series
A total of 321 patients treated in community hospitals or regional
cancer centres were included in the Elypse 1 study between
November 1995 and September 1996. In all, 20 (6%) experienced
FN after the first course of chemotherapy. In univariate analysis,
parameters correlated to the risk of FN were slightly different
from those observed in the CLB-1996 series: high-risk chemother-
apy regimens, age, PS X2, previous episodes of FN, tumour type,
but not gender, stage, bone marrow involvement, number of
Table 1 Clinical characteristics and correlation with febrile neutropenia
CLB-1996 Elypse 1 Elypse 0
N (%)
FN
N (%)
FN
N (%)
FN
950 N (%) P 321 N (%) P 329 N (%) P
Median age (range) 55 (18–86) 58 (18–86) 46 (18–80)
Age (years) 0.34 0.02 0.03
p60 575 (60) 58 (10) 134 4 (3) 238 (72) 73 (31)
>60 375 (40) 34 (9) 175 16 (9) 91 (28) 17 (19)
Gender 0.01 0.88 0.32
F 514 (54) 61 (12) 194 (62) 12 (6) 169 (5116) 50 (34)
M 436 (46) 31 (7) 121 (38) 8 (7) 49 40 (25)
Diagnostic o0.001
a o0.001 o0.001
a
All carcinoma 734 (77) 58 (8) 281 12 (4) 138 (42) 15 (4)
Breast 224 (24) 28 (12) 106 (33) 2 (2) 48 (15) 3 (6)
Colon-rectum 91 (9) 1 (1) 55 (17) 0 (0) 10 (3) 0 (0)
Ovary 86 (9) 13 (15) 36 (11) 3 (9) 10 (3) 0 (0)
Head and neck 97 (10) 4 (4) 21 (7) 2 (10) 12 (4) 0 (0)
Lung cancer 55 (6) 4 (8) 9 (3) 1 (11) 11 (3) 3 (27)
Lymphoma/myeloma 72 (8) 16 (22) 21 (7) 4 (20) 115 (35) 52 (45)
Sarcomas 64 (7) 10 (15) 15 (5) 4 (27) 48 (15) (20) (42)
Germ cells tumor 29 (3) 4 (13) 7 (2) 2 (29) 28 (8) 3 (11)
Others 232 (24) 12 (5) 51 (16) 2 (4) 48 (15) 2 (4)
High-risk CT 0.003 0.001 0.001
Yes 89 (10) 17 (19) 24 (8) 7 (29) 142 (43) 70 (49)
No 861 (90) 75 (9) 291 (92) 13 (4) 187 (572) 20 (11)
PS 0.03 0.04 0.07
b
0–1 801 (84) 71 (9) 251 (79) 14 (6) 98 (87)
b 23
b (22)
>1 149 (16) 21 (14) 40 (12) 6 (15) 14 (13)
b 6
b (42)
No. of previous courses of CT 0.09 0.49 0.99
0 450 (47) 47 (10) 97 (30) 9 (9) 106 (32) 29 (27)
>1 600 (53) 45 (7) 224 (70) 11 (5) 223 (8) 61 (27)
Metastases 0.09 0.33 0.33
Yes 121 (13) 17 (14) 95 (46) 4 (4) 95 (46) 4 (4)
No 829 (87) 75 (9) 113 (54) 9 (8) 113 (54) 9 (8)
Bone marrow metastases 0.69 0.17
Yes NA NA NA 16 2 11 21 11 (52)
No NA NA NA 132 11 8 67 24 (36)
Comorbidity 0.52
Yes 163 (17) 16 (10) NA NA NA NA NA NA
No 787 (83%) 76 (9.7) NA NA NA NA NA NA
Previous FN 0.005
Yes NA NA NA 7 2 29 NA NA NA
No NA NA NA 278 13 4.7 NA NA NA
aLymphoma or myeloma vs sarcoma vs carcinomas and others.
bPS at the date of the course was available in 112 of the 329 patients. P value refers to w
2 test for association
between risk factor and FN. FN=febrile neutropenia; NA=not available.
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lprevious chemotherapy cycles, were found correlated to the
risk of FN (Table 1). Of note, age 460 was associated with a
significantly higher incidence of FN in the Elypse 1 series, while the
opposite was observed in the Elypse 0 series, probably because of
the use of different regimens. Age was not an independent
prognostic factor for FN in any series (not shown). Day 5
lymphocytes p700ml
 1 were the only biological parameter
significantly correlated to the risk of FN in the Elypse 1 series.
Although the incidence of FN in patients with low day 1
lymphocyte count was two-fold that of remaining patients, the
difference was not significant (Table 2).
A logistic regression was performed to identify independent risk
factors for FN in the Elypse 1 series: using logistic regression, the
only two independent parameters were day 5 lymphocytes
p700ml
 1 (b¼1.0770.51, P¼0.034) and high-risk chemotherapy
regimen (b¼1.8670.55, Po0.001), in agreement with our
previously described day 5 risk model (Blay et al, 1996). The
observed incidences of FN were nine of 242 (3.7%), six of 61 (10%),
and five of 11 (45%), respectively, in patients with none, one, and
both of the two risk factors of the day 5 risk model.
Comparison of day 1 and day 5 model in the Elypse series
The ‘day 1’ risk model was then tested in the Elypse 1 and 0 series,
and a subgroup of patients with a risk of FN440% was identified
in both series (Table 4). However, only 5% of all patients who
Table 2 Blood cell count and FN
CLB-1996
No. of
FN Elypse 1
No. of
FN Elypse 0
No. of
FN
patients (%) N (%) v
2 P patients (%) N (%) v
2 P patients (%)
a N (%) v
2 P
Day 1 lymphocyte count 0.05 0.18 0.08
p700ml
 1 204 (22) 27 (14) 36 (11) 4 (11) 227 (82) 48 (21)
>700ml
 1 746 (78) 65 (8) 277 (89) 16 (6) 49 (18) 16 (33)
Day 5 lymphocyte count NA 0.004 o0.001
p700ml
 1 NA NA 57 (21) 9 (16) 146 (44) 71 (49)
>700ml
 1 NA NA 253 (79) 11 (4) 183 (56) 19 (10)
Day 1 PMN count 0.41 0.67 0.16
p1500ml
 1 19 (2) 2 (9) 18 (8) 1 (6) 23 (8) 8 (35)
>1500ml
 1 931 (98) 90 (9) 295 (92) 19 (6) 253 (92) 56 (22)
Day 5 PMN count NA 0.45 0.07
p1500ml
 1 NA NA 9 (3) 1 (5) 16 (5) 7 (44)
>1500ml
 1 NA NA 301 (97) 19 (6) 257 (95) 59 (23)
Day 1 platelet count 0.13 0.61 o0.001
o150000ml
 1 89 (9) 13 (14) 14 (5) 1 (7) 23 (9) 17 (71)
>150000ml
 1 861 (91) 79 (9) 299 (95) 19 (6) 253 (91) 47 (19)
Day 1 haemoglobin count 0.22 0.10 0.04
o12gdl
 1 448 (47) 49 (11) 161 (51) 7 (4) 160 (58) 44 (27)
>12gdl
 1 502 (53) 43 (9) 154 (49) 13 (8) 117 (42) 20 (17)
aMissing data in 56 patients. FN=febrile neutropenia, NA=not available. P value refers to w
2 test for association between risk factor and FN.
Table 3 Independent risk factors for FN in the CLB-1996 series
b s.e. v
2 P Odds ratio 95% CI
Intercept  2.5 0.114 300.9 o0.001
High-risk chemotherapy 0.99 0.300 10.93 0.001 2.69 1.07–2.8
Day 1 lymphocytes p700ml
 1 0.56 0.246 5.08 0.02 1.75 1.49–4.8
Table 4 Incidence of FN (N, %) in the three subgroups according to the two risk models
ELYPSE 0 (N=329) ELYPSE 1 (N=321) CLB-1996 (N=950)
Model 1 (day 5) Model 2 (day 1)
a Model 1 (day 5) Model 2 (day 1) Model 2 (day 1)
In the whole group 90/329 (27%) 20/321 (6%) 92/950 (10%)
Lymphocyte p700ml
b 71/146 (48%) 16/49 (33%) 5/31 (16%) 4/36 (11%) 27/204 (14%)
Two risk factors 56/82 (69%) 7/18 (61%) 5/11 (45%) 3/6 (50%) 4/9 (44%)
One risk factor 30/125 (24%) 40/111 (36%) 6/61 (10%) 5/48 (9%) 36/275 (13%)
No risk factor 4/122 (3%) 13/135 (9%) 9/242 (3.7%) 12/264 (4%) 52/666 (8%)
aData on day 1 lymphocyte count were missing for 52 patients including 26 who experienced FN.
bOn day 5 for model 1; on day 1 for model 2.
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lexperienced FN belonged to the high-risk group in the CLB-1996
series; this proportion was 15% in the Elypse 1 series and 12% in
the Elypse 0 series (Blay et al, 1996). In contrast, 25 and 62% of the
patients who experienced FN were in the high-risk group of the
day 5 model in the Elypse 1 and 0 series, respectively. Patients with
lymphocyte count 4700ml
 1 at day 1 and p700ml
 1 at day 5 were
found to have a similar incidence of FN than patients with day-1
lymphocytes p700ml
 1 (Table 4). Among the three series, the
positive predictive values of the day 1 and day 5 risk models were
42 and 66%, while the NPVs were 89 and 91%, respectively. The
specificity of the day 1 and day 5 risk models were 98 and 94%;
however, the sensibility of the day 1 model was lower than that of
the day 5 model (8 vs 55%).
DISCUSSION
FN is a frequent and life-threatening complication of cancer
chemotherapy, which can be partially prevented by the prophy-
lactic use of haematopoı ¨etic growth factors (G-CSG or GM-CSF) or
by a reduction of the dose of chemotherapy (The American Society
of Clinical Oncology, 1994; Blay et al, 1995; Boogaerts et al, 1995;
Bennett et al, 1999). Haematopoietic growth factors can be given in
secondary prophylaxis, after a first episode of FN or as primary
prophylaxis, that is, prior to any event. In the latter situation, the
selection of patients at high risk for FN is necessary to reduce the
risk of giving an unnecessary treatment with possible side effects
and a significant cost. Several scientific oncology societies (The
American Society of Clinical Oncology, 1994; Blay et al, 1995;
Boogaerts et al, 1995; Bennett et al, 1999) have proposed guidelines
for the prescription of haematopoietic growth factors: these factors
should be given preferentially to patients with a ‘relatively high
risk’ of FN in whom dose reduction could affect significantly the
therapeutical goal, that is, response to chemotherapy or survival
(The American Society of Clinical Oncology, 1994; Blay et al, 1995;
Boogaerts et al, 1995; Bennett et al, 1999).
The quantification of the individual risk for a given patient
remains uneasy in clinical practice. Although the dose of
chemotherapy significantly increases the risk of FN, this complica-
tion may occur after almost any type of chemotherapy regimen
(Miser et al, 1987; Tannock et al, 1988; Velasquez et al, 1988;
Coiffier et al, 1989; Elias et al, 1989; Nichols et al, 1991). Individual
parameters of the patient contribute, therefore, significantly to the
risk of FN, in addition to the type and dose of chemotherapy. The
identification of these individual risk factors is an important
objective of future studies in this field (The American Society of
Clinical Oncology, 1994; Blay et al, 1995; Bennett et al, 1999).
However, a limited number of studies have attempted to identify
these individual risk factors in a general population of cancer
patients. In a previous study, we reported that the dose of
chemotherapy and a rapid (day 5) lymphopenia (p700ml
 1)
following the administration of chemotherapy were independent
risk factors for FN. This enabled us to identify a subgroup of
patients with a high risk of FN (440%) in a general population of
cancer patients treated in comprehensive cancer centres (Blay et al,
1996).
The results presented here show that the previous model (day 5
model) is also efficient to identify a subgroup at high risk for FN
among patients treated in community hospital with cytotoxic
chemotherapy. The same risk factors for FN, that is high-
risk chemotherapy and day 5 lymphocyte count p700ml
 1, had
independent prognostic value in patients treated in cancer centres
and in community hospitals, further supporting the validity of the
model.
Two reasons prompted us to investigate an alternative risk
model using day 1 blood cell count. First, in the Elypse 1 series,
patients with day 1 lymphopenia p700ml
 1 were found to have a
two-fold increase of the risk of FN as compared to the remaining
patients, and similar observations were made in the previous
Elypse 0 series (Blay et al, 1996). This parameter may have failed to
reach significance in these series possibly because of an
insufficient power of the study. Second, the requirement of
haematological parameters measured at day 5 of chemotherapy
in order to identify high-risk patients is not optimally practical for
growth factor prescription or other prophylactic measures in an
outpatient setting. It would therefore be useful to have a model
enabling the identification of high-risk patients at day 1.
The analysis of risk factors for FN in the CLB-1996 population,
which comprises 950 patients in whom only day 1 haematological
parameters were available, showed that additional clinical and
biological parameters had a significant predictive value for FN.
Day 1 lymphopenia p700ml
 1 significantly correlated to the risk
of FN in univariate analysis. Age o60 was not correlated to the
risk of FN in the CLB-1996 series. In contrast, in the Elypse 0
series, which includes mainly patients treated within wards
devoted to dose-intensive chemotherapy regimens, age 460 was
associated with a reduced incidence of FN, because of the less
frequent use of dose-intensive regimens in this subgroup of
patients. These discrepancies illustrate the variability of risk
factors for FN in different selected series of patients. It is important
to note, however, that age was not an independent prognostic
factor for any series in this study.
Indeed, using logistic regression, day 1 lymphopenia p700ml
 1
and the dose of chemotherapy remained the only two independent
prognostic parameters in the CLB-1996 series in which day 5 blood
count was not available. This enables one to distinguish patients
with 0, 1 and both of these two risk factors with this ‘day 1’ risk
model. In the latter group, 44% of the patients of the CLB-1996
series experienced FN. This variant risk model for FN (day 1
model) also identified groups of patients at high risk for FN in the
Elypse 1 and 0 series, with an observed incidence of FN of 50 and
61%, respectively, confirming the validity of the day 1 model to
predict FN.
However, the sensitivity of this day 1 model was found to be
lower than that of the day 5 model, when compared in the
Elypse 1 or Elypse 0 series. Indeed, a 40–50% of patients
with lymphocyte count 4700ml
 1 will experience a drop under
700ml
 1 at day 5, and these patients were found to be at similar
risk for FN than patients with lymphocyte counts p700ml
 1 at
day 1. Day 5 lymphopenia is a more sensitive criteria than
day 1 lymphopenia to identify patients at risk for FN. The
‘day 5’ risk model is therefore more powerful to detect patients
who will experience FN, in particular in cohorts receiving
dose-intensive regimens. It is possible that the phenotypic analysis
of depleted lymphocyte subtypes at day 1 may improve the
sensitivity of the day 1 model: in a recently reported study, patients
with both day 1 CD4+ and CD56+ lymphopenia were found to be
at high risk for FN in a series of 226 patients (Blay et al, 2001). The
capacity of these parameters to identify a higher proportion of
patients who will experience FN is currently being tested
prospectively.
Finally, it is noteworthy that both the day 1 and day 5 models
were more ‘sensitive’ in the Elypse 0 series which includes a high
proportion (43%) of ‘high-risk’ chemotherapy regimens, as
compared to the Elypse 1 and CLB-1996, in which 8 and 10% of
patients received high-risk regimens. In these latter series, in
which a significantly higher proportion of all patients have one or
no risk factors for FN, a lower proportion of FN occurs within the
high-risk group. The models described here are therefore more
useful in groups of patients in whom a high proportion receive
‘high-risk’ chemotherapy.
In conclusion, these results indicate that the previously
described risk model for FN, relying on day 5 lymphopenia and
the dose of chemotherapy, is efficient for the identification of
patients who will experience FN in cohorts treated in community
hospitals, although its sensitivity is lower than for patients treated
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lin comprehensive cancer centre, because of the higher proportion
of patients receiving high-risk chemotherapy. Day 1 lymphopenia
identifies a small subgroup of patients at risk for FN among
patients receiving high-risk regimens, but is much less sensitive
than day 5 lymphopenia in all series tested.
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